Skip to main content

Multiple Sclerosis News (Page 2)

Related terms: MS

Parents' Smoking Could Raise Risk for MS in Kids

WEDNESDAY, Dec. 11, 2024 – For children genetically predisposed to develop multiple sclerosis (MS), exposure to cigarette smoke in the family home could raise that risk even higher, new research...

Social Determinants of Health Linked to Brain MRI Outcomes in Pediatric MS

MONDAY, Dec. 2, 2024 – For patients with pediatric-onset multiple sclerosis (POMS), social determinants of health (SDOH) are associated with worse brain magnetic resonance imaging (MRI) outcomes,...

Kids From Poorer Homes May Have Worse Outcomes If MS Strikes

FRIDAY, Nov. 29, 2024 – A child from a poorer neighborhood is more prone to severe illness once they develop multiple sclerosis (MS) compared to children growing up in more affluent areas, new...

Generic Medications Can Keep OOP Costs Down for Neurological Conditions

WEDNESDAY, Oct. 30, 2024 – Generic medications reduce the out-of-pocket (OOP) costs for common neurological conditions, apart from multiple sclerosis, for which costs continue to increase, according...

Costs for MS, Parkinson's and Alzheimer's Meds Keep Rising

THURSDAY, Oct. 31, 2024 – A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that same patient spent $2,378 annually, a new report...

What Works Best to Ease MS-Linked Fatigue? New Study Finds Out

FRIDAY, Oct. 25, 2024 – Medication and behavioral therapy are both effective in combatting fatigue caused by multiple sclerosis (MS), either separately or together, a new study finds. MS patients...

Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue

FRIDAY, Oct. 25, 2024 – Cognitive behavioral therapy (CBT), modafinil, and their combination are equally beneficial for multiple sclerosis fatigue, according to a study published in the November...

MS Might Raise a Person's Odds for Cancer

THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...

Cancer Incidence Increased for People With Multiple Sclerosis

WEDNESDAY, Oct. 9, 2024 – Cancer incidence is increased overall in people with multiple sclerosis (PwMS), with considerable differences depending on cancer type, age, and sex, according to a study...

FDA Approves Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) Twice-A-Year Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis

South San Francisco, CA – September 13, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has...

European Committee for Treatment and Research in Multiple Sclerosis, Sept. 18-20

The annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis was held from Sept. 18 to 20 in Copenhagen, Denmark, and drew more than 8,500 delegates from around the ...

Aggressive, Early Disease-Modifying Therapy May Slow MS Progression

FRIDAY, Sept. 27, 2024 – Reducing or preventing paramagnetic rim lesions (PRLs) could significantly slow multiple sclerosis (MS) progression, according to a study presented at the annual meeting of...

Anti-CD20 Therapy Shows No Effect on Disability Progression in MS

THURSDAY, Sept. 26, 2024 – For patients with primary progressive multiple sclerosis (PPMS), the time to confirmed disability progression (CDP) does not differ for those who are anti-CD20-treated and...

FDA Approves Injectable Ocrevus Zunovo for Relapsing, Progressive MS

THURSDAY, Sept. 26, 2024 – The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection...

Guidelines Provided for Diagnosis of Pediatric, Late-Onset Multiple Sclerosis

TUESDAY, Sept. 24, 2024 – In a clinical review conducted by an international committee of multiple sclerosis (MS) experts in pediatric and adult MS and published online Sept. 16 in JAMA Neurology,...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

prednisone, methylprednisolone, Medrol, prednisolone, valacyclovir, dexamethasone, Tecfidera, Ocrevus, Gilenya, dimethyl fumarate, Aubagio